Vaccine vs COVID - Common Discussion of COVID-19 Vaccines |Pfizer Moderna CureVac Novavax AstraZeneca Janssen Sanofi-GSK Valneva

Vaccine vs COVID - Common Discussion of COVID-19 Vaccines |Pfizer Moderna CureVac Novavax AstraZeneca Janssen Sanofi-GSK Valneva Telegram | DID YOU KNOW?

The S&P 500 slumped 1.8% on Monday and Tuesday, thanks to China Evergrande, the Chinese property company that looks like it is ready to default on its more-than $300 billion in debt. Cries of the next Lehman Brothers—or maybe the next Silverado?—echoed through the canyons of Wall Street as investors prepared for the worst.

The seemingly negative pandemic effects and resource/product shortages are encouraging and allowing organizations to innovate and change.The news of cash-rich organizations getting ready for the post-Covid growth economy is a sign of more than capital spending plans. Cash provides a cushion for risk-taking and a tool for growth.